Prescription of Anticholinergic Drugs in Patients With Schizophrenia: Analysis of Antipsychotic Prescription Patterns and Hospital Characteristics.

anticholinergic drugs antipsychotic monotherapy antipsychotic polypharmacy first-generation antipsychotics schizophrenia second-generation antipsychotic (SGA)

Journal

Frontiers in psychiatry
ISSN: 1664-0640
Titre abrégé: Front Psychiatry
Pays: Switzerland
ID NLM: 101545006

Informations de publication

Date de publication:
2022
Historique:
received: 28 11 2021
accepted: 04 04 2022
entrez: 3 6 2022
pubmed: 4 6 2022
medline: 4 6 2022
Statut: epublish

Résumé

In several clinical guidelines for schizophrenia, long-term use of anticholinergic drugs is not recommended. We investigated the characteristics of the use of anticholinergics in patients with schizophrenia by considering psychotropic prescription patterns and differences among hospitals. A cross-sectional, retrospective prescription survey at the time of discharge was conducted on 2027 patients with schizophrenia from 69 Japanese hospitals. We examined the relations among psychotropic drug prescriptions regarding anticholinergic prescription. We divided the hospitals into three groups-low rate group (LG), medium rate group (MG), and high rate group (HG)-according to their anticholinergic prescription rates, and analyzed the relationship between anticholinergic prescription rates and antipsychotic prescription. Anticholinergic drugs were prescribed to 618 patients (30.5%), and the prescription rates were significantly higher for high antipsychotic doses, antipsychotic polypharmacy, and first-generation antipsychotics (FGAs) use. The anticholinergic prescription rate varied considerably among hospitals, ranging from 0 to 66.7%, and it was significantly higher in patients with antipsychotic monotherapy, antipsychotic polypharmacy, and normal and high doses of antipsychotics in HG than in those LG and MG. The anticholinergics prescription rate in patients with second-generation antipsychotic monotherapy in HG was also significantly higher than in those LG and MG; however, the difference was no longer significant in patients with FGA monotherapy. Conclusively, in addition to high antipsychotic doses, antipsychotic polypharmacy, and FGA use, hospital characteristics influence the prescribing of anticholinergic drugs.

Identifiants

pubmed: 35656353
doi: 10.3389/fpsyt.2022.823826
pmc: PMC9152135
doi:

Types de publication

Journal Article

Langues

eng

Pagination

823826

Informations de copyright

Copyright © 2022 Hori, Yasui-Furukori, Hasegawa, Iga, Ochi, Ichihashi, Furihata, Kyo, Takaesu, Tsuboi, Kodaka, Onitsuka, Okada, Murata, Kashiwagi, Iida, Hashimoto, Ohi, Yamada, Ogasawara, Yasuda, Muraoka, Usami, Numata, Takeshima, Yamagata, Nagasawa, Tagata, Makinodan, Kido, Katsumoto, Komatsu, Matsumoto, Kubota, Miura, Hishimoto, Watanabe, Inada, Kawasaki and Hashimoto.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Sleep Med. 2022 Jan;89:23-30
pubmed: 34875519
Hum Psychopharmacol. 2012 Jan;27(1):70-5
pubmed: 22249957
Can J Psychiatry. 1994 Mar;39(2):74-84
pubmed: 7908605
Neuropsychopharmacol Rep. 2022 Jun;42(2):221-225
pubmed: 35272393
BMC Med. 2018 May 21;16(1):76
pubmed: 29783964
Am J Psychiatry. 2020 Sep 1;177(9):868-872
pubmed: 32867516
J Clin Psychiatry. 2007 Aug;68(8):1218-25
pubmed: 17854246
Psychiatry Clin Neurosci. 2019 Aug;73(8):476-485
pubmed: 31077519
Pharm World Sci. 2007 Jun;29(3):126-30
pubmed: 17333501
World J Biol Psychiatry. 2012 Jul;13(5):318-78
pubmed: 22834451
Schizophr Res. 2006 Sep;86(1-3):138-46
pubmed: 16793238
Lancet. 2012 Dec 15;380(9859):2129-43
pubmed: 23245605
Pharmacopsychiatry. 2011 May;44(3):114-8
pubmed: 21491361
Psychiatry Clin Neurosci. 2020 Feb;74(2):149-155
pubmed: 31707749
Am J Psychiatry. 2004 Jan;161(1):116-24
pubmed: 14702259
Curr Opin Psychiatry. 2007 May;20(3):268-72
pubmed: 17415081
Australas Psychiatry. 2017 Dec;25(6):600-602
pubmed: 28875719
Br J Clin Pharmacol. 2009 Aug;68(2):238-42
pubmed: 19694744
Psychiatry Clin Neurosci. 2019 Oct;73(10):642-648
pubmed: 31437336
J Psychopharmacol. 2020 Jan;34(1):3-78
pubmed: 31829775
Acta Psychiatr Scand Suppl. 1987;334:1-100
pubmed: 2887090
Asian J Psychiatr. 2019 Oct;45:74-80
pubmed: 31520884
Acta Psychiatr Scand. 2006 Feb;113(2):135-41
pubmed: 16423165
Psychiatry Clin Neurosci. 2014 Jan;68(1):37-49
pubmed: 24102938
Arch Gen Psychiatry. 1992 Jul;49(7):538-44
pubmed: 1352677
Neuropsychopharmacol Rep. 2022 Mar;42(1):3-9
pubmed: 34854260
Neuropsychopharmacol Rep. 2021 Jun;41(2):199-206
pubmed: 33704931
Psychiatry Clin Neurosci. 2020 May;74(5):289-293
pubmed: 31994282
Psychiatry Clin Neurosci. 2019 Jul;73(7):394-399
pubmed: 30968478
Biomed Res Int. 2014;2014:656370
pubmed: 24995318
J Psychiatr Res. 2013 Dec;47(12):1843-8
pubmed: 24054464
Br J Psychiatry. 2011 Oct;199(4):266-8
pubmed: 22187726
Psychiatry Clin Neurosci. 2022 Jan;76(1):1-14
pubmed: 34716732
Psychiatry Res. 2017 Sep;255:198-203
pubmed: 28578178
J Psychopharmacol. 2012 Sep;26(9):1167-74
pubmed: 22651987
Asian J Psychiatr. 2021 Sep;63:102744
pubmed: 34325252
Psychiatry Clin Neurosci. 2020 Dec;74(12):667-669
pubmed: 32881226
Neuropsychiatr Dis Treat. 2013;9:1381-92
pubmed: 24092977
Psychiatry Res. 2007 Aug 30;152(2-3):165-72
pubmed: 17445906
Lancet. 2019 Sep 14;394(10202):939-951
pubmed: 31303314
Neuropsychiatr Dis Treat. 2014 Mar 26;10:527-33
pubmed: 24707178
Neuropsychopharmacol Rep. 2020 Sep;40(3):281-286
pubmed: 32602667
Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jan 15;35(1):78-83
pubmed: 20828595
Psychiatry Clin Neurosci. 2015 Aug;69(8):440-7
pubmed: 25601291
J Clin Psychopharmacol. 2011 Aug;31(4):497-502
pubmed: 21694629
Basic Clin Pharmacol Toxicol. 2020 Mar;126(3):183-192
pubmed: 31908124
Int J Neuropsychopharmacol. 2005 Sep;8(3):427-38
pubmed: 15804371

Auteurs

Hikaru Hori (H)

Department of Psychiatry, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.

Norio Yasui-Furukori (N)

Department of Psychiatry, Dokkyo Medical University School of Medicine, Tochigi, Japan.

Naomi Hasegawa (N)

National Institute of Mental Health, National Center of Neurology and Psychiatry, Kodaira, Japan.

Jun-Ichi Iga (JI)

Department of Neuropsychiatry Molecules and Function, Ehime University Graduate School of Medicine, Matsuyama, Japan.

Shinichiro Ochi (S)

Department of Neuropsychiatry Molecules and Function, Ehime University Graduate School of Medicine, Matsuyama, Japan.

Kayo Ichihashi (K)

Department of Neuropsychiatry, University of Tokyo Hospital, Tokyo, Japan.

Ryuji Furihata (R)

Agency for Student Support and Disability Resources, Kyoto University, Kyoto, Japan.

Yoshitaka Kyo (Y)

Department of Psychiatry, School of Medicine, Kitasato University, Tokyo, Japan.

Yoshikazu Takaesu (Y)

Department of Neuropsychiatry, Graduate School of Medicine, University of the Ryukyus, Nishihara, Japan.

Takashi Tsuboi (T)

Department of Neuropsychiatry, Kyorin University School of Medicine, Mitaka, Japan.

Fumitoshi Kodaka (F)

Department of Psychiatry, The Jikei University School of Medicine, Tokyo, Japan.

Toshiaki Onitsuka (T)

Department of Neuroimaging Psychiatry, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Tsuyoshi Okada (T)

Department of Psychiatry, Jichi Medical University, Tochigi, Japan.

Atsunobu Murata (A)

National Institute of Mental Health, National Center of Neurology and Psychiatry, Kodaira, Japan.

Hiroko Kashiwagi (H)

National Institute of Mental Health, National Center of Neurology and Psychiatry, Kodaira, Japan.
Department of Psychiatry, National Center of Neurology and Psychiatry Hospital, Kodaira, Japan.

Hitoshi Iida (H)

Department of Psychiatry, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.

Naoki Hashimoto (N)

Department of Psychiatry, Hokkaido University Graduate School of Medicine, Sapporo, Japan.

Kazutaka Ohi (K)

Department of Psychiatry, Gifu University Graduate School of Medicine, Gifu, Japan.

Hisashi Yamada (H)

National Institute of Mental Health, National Center of Neurology and Psychiatry, Kodaira, Japan.
Department of Neuropsychiatry, Hyogo College of Medicine, Nishinomiya, Japan.

Kazuyoshi Ogasawara (K)

Center for Postgraduate Clinical Training and Career Development, Nagoya University Hospital, Nagoya, Japan.

Yuka Yasuda (Y)

National Institute of Mental Health, National Center of Neurology and Psychiatry, Kodaira, Japan.
Life Grow Brilliant Mental Clinic, Medical Corporation Foster, Osaka, Japan.

Hiroyuki Muraoka (H)

Department of Psychiatry, Tokyo Women's Medical University, Tokyo, Japan.

Masahide Usami (M)

Department of Child and Adolescent Psychiatry, Kohnodai Hospital, National Center for Global Health and Medicine, Ichikawa, Japan.

Shusuke Numata (S)

Department of Psychiatry, Graduate School of Biomedical Science, Tokushima University, Tokushima, Japan.

Masahiro Takeshima (M)

Department of Neuropsychiatry, Akita University Graduate School of Medicine, Akita, Japan.

Hirotaka Yamagata (H)

Division of Neuropsychiatry, Department of Neuroscience, Yamaguchi University School of Medicine, Yamaguchi, Japan.

Tatsuya Nagasawa (T)

Department of Neuropsychiatry, Kanazawa Medical University, Uchinada, Japan.

Hiromi Tagata (H)

Department of Neuropsychiatry, Toho University Graduate School of Medicine, Tokyo, Japan.

Manabu Makinodan (M)

Department of Psychiatry, Nara Medical University School of Medicine, Kashihara, Japan.

Mikio Kido (M)

Toyama City Hospital, Toyama, Japan.
Department of Neuropsychiatry, University of Toyama Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan.

Eiichi Katsumoto (E)

Katsumoto Mental Clinic, Oosaka, Japan.

Hiroshi Komatsu (H)

Department of Psychiatry, Tohoku University Hospital, Sendai, Japan.

Junya Matsumoto (J)

National Institute of Mental Health, National Center of Neurology and Psychiatry, Kodaira, Japan.

Chika Kubota (C)

Department of Psychiatry, National Center of Neurology and Psychiatry Hospital, Kodaira, Japan.

Kenichiro Miura (K)

National Institute of Mental Health, National Center of Neurology and Psychiatry, Kodaira, Japan.

Akitoyo Hishimoto (A)

Department of Psychiatry, Yokohama City University Graduate School of Medicine, Yokohama, Japan.

Koichiro Watanabe (K)

Department of Neuropsychiatry, Kyorin University School of Medicine, Mitaka, Japan.

Ken Inada (K)

Department of Psychiatry, Tokyo Women's Medical University, Tokyo, Japan.

Hiroaki Kawasaki (H)

Department of Psychiatry, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.

Ryota Hashimoto (R)

National Institute of Mental Health, National Center of Neurology and Psychiatry, Kodaira, Japan.

Classifications MeSH